CHMP recommends Pomalidomide Celgene as a treatment for Multiple Myeloma
Celgene International S�rl, a wholly-owned subsidiary of Celgene Corporation has announced that the European Medicines Agency�s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Pomalidomide Celgene in combination with dexamethasone for the treatment of relapsed and refractory Multiple Myeloma (rrMM) in patients who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression while on their last therapy.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma